Kornimate/medical-research-clean huggingface dataset:
clinical classification and imaging markers in patients of obesity

Conditions: Obesity; fMRI; Clinical Classification

Summary: this is an observational study to explore the etiology and clinical classification in patients with obesity and to achieve personalized treatment.

in this project, individuals with obesity and control individuals were recruited and followed up every year. clinical neuropsychological scores, olfactory function tests, and functional magnetic resonance imaging (fmri) were performed to describe the brain function characteristics under different odor stimulation in fasting and after eating, and to explore the pathogenesis and clinical classification of obese patients. the correlation analysis between imaging analysis values and clinical laboratory data, neuropsychological scores and olfactory behavior scores was performed to explore indicators related to cognitive decline and provide new insights into the etiology and classification of obese patients. combined with clinical evaluation and imaging examination, the changes of cognitive behavior and brain structure and function in obese patients were followed up.

Eligibility criteria:
inclusion criteria: * patients with bmi≥28kg/m2 * aged 18-65 years of both sexes, right-handed * at least 6 years of education * patients agreed and signed the informed consent exclusion criteria: * fewer than 6 years of education * left-handedness * dementia * acute metabolic complications such as diabetic ketoacidosis * hyperglycaemic hyperosmolar state and hypoglycaemic coma within the previous 3 months; history or presence of neurological or psychiatric disorders; * presence of hypothyroidism; * history of malignancy, or severe kidney or liver dysfunction.
influence of lavender oil on vital signs in oral surgery patients

Conditions: Dental Anxiety; Sedative; Anxiety Disorder

Summary: the aim of this study is to investigate the impact of lavender oil (lavandula angustifolia) on anxiety, mood, vital signs (blood pressure, respiratory rate, heart rate and saturation) for oral surgery patients.

lavender oil has sedative properties. oral surgical procedures have been proven as to be the greatest concern among dental practices for patients. limited randomized clinical trials have demonstrated evidence-based results of lavender oil, despite being the most effective essential oil for anxiety and stress. the hypothesis of the present study was that the inhalation of lavender oil prior to oral surgical procedures may reduce anxiety and consequently may effect intra and post-operative blood pressure, inspiration and heart rate.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of wisdom tooth * must be similar in age-height-weight * must be similar socio-culturally exclusion criteria: * under 18 years of age * taking psychotropic medication or psychiatric treatment * systemically unhealthy patients * pregnants

Keywords: lavandula phytotherapy aromatherapy dental anxiety anaesthesia
olanzapine versus aripiprazole in the treatment of acutely ill patients with schizophrenia

Conditions: Schizophrenia

Summary: the purposes of this study are to assess similarities and differences in the efficacy (how well the drug works), safety, and side effects of olanzapine and aripiprazole in patients with schizophrenia, schizoaffective disorder, or schizophreniform disorder.


Eligibility criteria:
inclusion criteria: * patients must have schizophrenia, schizoaffective disorder, or schizophreniform disorder * patients must be agitated * patients must display psychotic symptoms * patients must be inpatients who are expected to stay in the hospital for at least 5 days * patients must be 18 to 55 years of age exclusion criteria: * patients may not be hospitalized for greater than 72 hours prior to study start * patients may not have received more than one dose of olanzapine or aripiprazole within 72 hours prior to study start * patients may not be actively suicidal * patients may not be diagnosed with substance-induced psychosis or substance dependence * patients may not have acute, serious, or unstable medical conditions
pharmacokinetics of hr17031 injection in healthy subjects

Conditions: Type 2 Diabetes Mellitus

Summary: to compare the pharmacokinetics and safety of hr17031 injection, shr20004 injection and/or ins068 injection in healthy subjects


Eligibility criteria:
inclusion criteria: 1. body mass index (bmi) ranges from 18 to 27 kg/m2 (both ends included), and the body weight is ≥50 kg for men and ≥45 kg for women； 2. fasting blood glucose during the screening is \< 6.1 mmol/l； exclusion criteria: 1. it has clinical significance for abnormalities laboratory examination, if there is a clear reasonable reason, can be retested within a week, with the retest results whether the subject meets the requirements 2. severe systemic disease, or a prior history of pancreatitis or other systemic problems within 1 month prior to screening; 3. participate in any clinical trial of a drug or medical device within 3 months prior to screening (subject to signed informed consent)
a comparison of visual function after bilateral implantation of presbyopia-correcting intraocular lenses (iols)

Conditions: Cataract

Summary: the purpose of this study is to prospectively evaluate postoperative visual and refractive parameters in a series of subjects bilaterally implanted with the acrysof® iq restor® +3 versus those bilaterally implanted with the tecnis multifocal 1-piece.


Eligibility criteria:
inclusion criteria: * diagnosed with bilateral cataracts * candidate for presbyopic lens exclusion criteria: * \>1 diopter (d) preoperative astigmatism by keratometry (k)readings * pre-existing conditions that could skew the results

Keywords: presbyopia intraocular lens
acute changes in the mineral metabolism after a high phosphorous containing meal in dialysis patients

Conditions: Chronic Kidney Disease Stage 5; Mineral Metabolism Disorder

Summary: the purpose of the study is to investigate whether a high phosphorous containing meal causes acute changes in p-phosphate levels in patients with dialysis-dependent kidney failure.

disturbances in the mineral metabolism and especially the phosphate metabolism is associated with increased risk of cardiovascular disease and death in patients with kidney failure. in the healthy population the kidney compensates for a high phosphorous intake by increase renal excretion of phosphate, but this is not possible for patients with kidney failure. due to this monitoring and controlling phosphate levels is an important clinical goal in treatment of kidney failure, and it is often achieved with a phosphorous poor diet and phosphate binders. currently this monitoring of the phosphate level is complicated by a poor understanding of how plasma phosphate acutely reacts to a phosphate rich meal. often patients may have consumed a phosphate rich meal shortly before their blood test is taken, which may have an acute impact on the plasma phosphate level in the blood test and complicated the task of assessing their chronic phosphate levels. to examine this problem, the investigators wish to conduct a randomized cross-over trial, where peritoneal dialysis patients are recruited and randomly assigned to consume either a meal either high or low in phosphate on the first day of trial and the opposite in the second. with blood tests just before and during 5 hours after the meal, the investigators will examine plasma-phosphate levels as well as other blood parameters of importance to the mineral metabolism to determine, whether a meal rich in phosphate causes significant changes in these test parameters compared to a meal poor in phosphate.

Eligibility criteria:
inclusion criteria: * ≥18 years of age * currently treated with peritoneal dialysis (apd or capd) * serum ionized calcium between 1.10 and 1.40 mmol/l for \>3 months * plasma phosphate between 0.7 and 3.0 mmol/l for \>3 months exclusion criteria: * earlier parathyroidectomized * other conditions, which hinders the participation in the trial
study for participants continuing from pfizer-sponsored palbociclib (a study medicine) studies

Conditions: Breast Cancer; Head and Neck Cancer

Summary: the purpose of this clinical trial is to provide study medicine(s) and learn about their safety. this study is seeking participants who: * have benefited from ongoing study treatment as determined by the study doctor in a pfizer-sponsored palbociclib parent study * must agree to follow the reproductive criteria * are willing and able to comply with all scheduled visits, treatment plans, and other study procedures * can give signed informed consent documents participants in this study will continue to receive treatment as they were in the parent study. the time by which participants will take part in this study is retrospective (after completed parent study). we will examine the experiences of people receiving the study medicine(s). this will help us determine if the study medicine(s) are safe. during this time, the participants will be monitored for the safety of the study medicine(s).

this is an open-label study to provide continued access to treatment for eligible participants who continue to derive clinical benefit as determined by the investigator from study intervention(s) in a pfizer-sponsored palbociclib clinical study (parent study)

Eligibility criteria:
inclusion criteria: * any participant who is receiving study treatment and deriving clinical benefit as determined by the investigator in a pfizer-sponsored palbociclib parent study * participants must agree to follow the reproductive criteria * participants who are willing and able to comply with all scheduled visits, treatment plans, and other study procedures * capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent document and protocol exclusion criteria: * any medical reason that, in the opinion of the investigator or sponsor, precludes the participant from inclusion in the study

Keywords: hormone receptor positive advanced breast cancer squamous cell carcinoma of the head and neck
alpps (liver partition and portal vein ligation) for two-stage hepatectomy for colorectal liver metastasis

Conditions: Colorectal Cancer

Summary: the aim of this study is evaluate the feasibility of early two-stage hepatectomy in patients with liver metastasis from colorectal cancer.

in france, each year around 36,000 new cases of colorectal cancers are registered responsible in 16,000 deaths because of liver metastasis. in case of bilobar metastasis, classic two-stage hepatectomy with portal embolization could be performed. an alternative to the classic surgery, early two stage hepatectomy, could be proposed to simplify the patient's management and to improve the resectability.

Eligibility criteria:
inclusion criteria: * potentially resectable liver metastasis from colorectal cancer * portal embolisation required * older than 18 years old exclusion criteria: * synchronous surgery on the colon or the rectum * extra hepatic metastasis * history of hepatectomy * pregnancy or breastfeeding

Keywords: two stage hepatectomy liver metastasis colorectal cancer
triglyceride rich lipoproteins and platelet activation in type 2 diabetes

Conditions: Type2 Diabetes

Summary: to investigate in vitro the effect of triglyceride rich lipoproteins (tgrl) obtained in type 2 diabetic women in the fasting state and following a randomized isocaloric lipid rich breakfast on control human platelets randomized comparison of butter versus chocolate spread in 2 groups of 15 patients


Eligibility criteria:
inclusion criteria: * menopausal women * hba1c ≥6,5 ou ≤10% * 27 ≤ bmi ≤40 kg/m2 exclusion criteria: * insulin therapy * fibrates or omega 3 fatty acids supplements * hormonal replacement therapy of menopause * glycemia \> 16 mmol/l * alcohol abuse (≥3 unit/day) * special dietary habits * history of bariatric surgery

Keywords: chylomicrons very low density lipoprotein saturated fat platelet function type 2 diabetes post prandial phase
nexavar post-marketing surveillance for rcc in japan: early access program

Conditions: Carcinoma, Renal Cell

Summary: this study is an early access program of 'nexavar post-marketing surveillance (pms) for renal cell carcinoma (rcc) in japan' which is a regulatory, local prospective and observational study for patients with unresectable or advanced rcc under real-life practice conditions. the objective of this study is to assess safety and effectiveness of nexavar at some limited sites which joined to clinical trial of nexavar, before available of it in the market. the enrollment period is 2 months, and patients who received nexavar will be recruited and followed one year since starting nexavar administration. the data of this study will be integrated into the nexavar pms and the data will not be analyzed and reported alone.


Eligibility criteria:
inclusion criteria: * patients who received nexavar for unresectable or advanced renal cell carcinoma exclusion criteria: * patients who are contraindicated based on the product label

Keywords: nexavar unresectable or advanced renal cell carcinoma
actinic keratoses treatment with metvix® in combination with light

Conditions: Actinic Keratoses

Summary: the main objective of this study is to compare efficacy and safety of metvix® natural daylight photodynamic therapy with those of metvix® conventional photodynamic therapy in subjects with mild actinic keratoses (intra-individual comparison)


Eligibility criteria:
inclusion criteria: * male or female above 18 years; * subject with clinical diagnosis of mild actinic keratosis (ak) on the face or the scalp with or without clinical diagnosis of moderate ak on the target areas (tas); exclusion criteria: * subject with clinical diagnosis of at least one severe ak on tas * subject with clinical diagnosis of other skin disease (including non-melanoma skin cancer) on the tas; * subject with pigmented ak on the tas
escitalopram in depressive patients with acute coronary artery syndrome

Conditions: Depressive Disorder; Coronary Disease

Summary: this study aimed to evaluate the efficacy and safety of escitalopram in the treatment of depressive patients with acute coronary artery syndrome (cas).

depression is common in patients with acute cas and increases cardiac morbidity and mortality. however, there are a few limited data available regarding the effects and safety of antidepressants for treating depression in patients with acute cas. this study aims to investigate whether escitalopram might be an effective treatment option for these patients.

Eligibility criteria:
inclusion criteria: * aged 18\~85 * diagnosed as acute cas (unstable angina or acute myocardial infarction) and being conducted coronary angiography * beck depression inventory \> 10 and major or minor depressive disorder by the dsm-iv criteria * with ability to complete various questionnaires * can understand the objective of the study and sign informed consent exclusion criteria: * occurrence of acute cas while the patient was hospitalized for another reason, except for cas * current cas developed less than 3 months after coronary artery bypass graft procedure * uncontrolled hypertension (systolic bp \> 180mmhg or diastolic bp \> 100mmhg) * resting heart rate \< 40/min * severe physical illnesses threatening life or interfering with the recovery from cas * persistent clinically significant laboratory abnormalities * concomitant use of class i antiarrhythmic medications; reserpine, guanethidine, clonidine, or methyldopa; anticonvulsants or neuroleptics * history of neuropsychiatric illnesses such as dementia, parkinson's disease, brain tumor, psychoses, alcoholism, and other substance dependence * pregnancy

Keywords: depression myocardial infarction angina, unstable
predicting medication response in obsessive compulsive disorder

Conditions: Obsessive Compulsive Disorder

Summary: in this study, the investigators hope to study a number of variables the investigators believe may help us predict why some people respond better to some medications than others. participants will be randomly assigned to receive one of two typical medications for ocd, clomipramine or escitalopram. individuals who would like to participate but who have previously tried one or both of these medications may instead take a newer drug, duloxetine, and undergo the identical procedures. the factors the investigators will be studying include demographics (i.e. age, gender, age of onset of ocd), genetic markers (such as variants in genes involved in breaking down drugs in the liver (cytochrome p450 system), and genes involved in several brain chemical systems, such as serotonin), the dimensions of ocd symptoms (i.e. checking, washing, and hoarding) and cortical inhibition. cortical inhibition will be measured transcranial magnetic stimulation and is being studied because deficits in this process may be important in the development of ocd. the investigators hypothesize that certain pretreatment clinical characteristics will correlate with poor treatment response including earlier age of onset, longer duration of illness, increased ybocs severity and presence of significant hoarding symptoms. the investigators expect that increasing degree of deficit in ci pre-treatment will predict poor treatment response, but that increase in ci from pre- to post-treatment will correlate with a positive treatment response. differences in genetic marker status for cytochrome p450 genes will correlate with tolerability and/or response, as well as differences in genetic marker status in slc1a1, grin2b, 5ht1b and 5ht2a will correlate with response.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of obsessive compulsive disorder * must be able to swallow tablets exclusion criteria: * history of stroke * history of parkinson's disease * history of epilepsy * clinical diagnosis of schizophrenia or schizoaffective disorder * clinical diagnosis of bipolar affective disorder * active suicidality

Keywords: ocd pharmacogenetics cortical inhibition genetics
indirect pulp treatment in primary molars

Conditions: Dental Caries

Summary: this study was conducted to evaluate the clinical and the radiographic success of dycal and vitrebond as indirect pulp treatment materials in primary molars.

evaluation of calcium hydroxide and resin modified glass ionomer liner clinically and radiographically as indirect pulp treatment materials in deep caries in primary molars.

Eligibility criteria:
inclusion criteria: in compliance with aapd, 2017 guidelines for pulp therapy "ipt is indicated in a primary tooth with no pulpitis or with reversible pulpitis when the deepest carious dentin is not removed to avoid a pulp exposure. the pulp is judged by clinical and radiographic criteria to be vital and able to heal from the carious insult" in addition to: i-subjects: 1. medically free children, their parent(s) accepts to sign the informed consent. 2. age range from 4-8 years. ii-molars: 1. presence of at least 1 primary molar with deep carious lesion extending to more than one half of the dentin on radiographic examination (to make the trial regardless of number of carious molars). 2. clinically: normal mobility and normal appearance of gingiva (vital teeth). 3. radiographically: normal roots without physiological resorption, normal lamina dura and normal periodontal membrane space (indicated for ipt). exclusion criteria: i-subjects: 1. uncooperative children. 2. parents unable to attend follow up visits (even after explaining the importance of recall visits). ii-molars: 1. history of spontaneous pain (to exclude reversible pulpitis). 2. clinically: presence of swelling, sinus, fistula or tooth mobility (to exclude non vital teeth). 3. radiographically: presence of radiolucent lesions at furcation or periapical region or external or internal resorption (to exclude teeth not indicated for ipt).

Keywords: indirect pulp primary calcium hydroxide resin modified glass ionomer children
the canadian mitral research alliance (camra) trial cardiolink-2

Conditions: Mitral Valve Prolapse

Summary: multicentre, double-armed, randomized controlled trial designed to compare mitral valve leaflet resection versus leaflet preservation with regards to the development of functional mitral stenosis following surgical repair of mitral valve prolapse. patients will be randomized (1:1) to receive: (1) mitral valve repair with a leaflet resection or (2) mitral valve repair with leaflet preservation (using polytetrafluoroethylene neochordae), followed by echocardiographic and clinical assessment at 12-months following surgery.

mitral valve repair has emerged as the preferred surgical treatment for mitral valve prolapse (mvp), a condition wherein the mitral valve does not close properly. one common strategy for mitral valve repair is leaflet resection, which involves removing part of one or both of the mitral leaflets that flop or bulge back (prolapse). another strategy is leaflet preservation, which involves placing man-made fibers (sutures) to more securely connect the mitral leaflets to the papillary muscles (muscles located in the ventricle). while both strategies are routinely used and lead to successful mitral valve repair, there is no clear evidence as to whether one strategy is better than the other in terms of long term outcome. the purpose of this study is to determine if one repair strategy (leaflet resection versus leaflet preservation) leads to better longer term patient outcomes. a total of 88 patients from 6 canadian centres will be randomly assigned to one of the two strategies. the primary outcome will be functional mitral stenosis (ms) as assessed by 12-month mean mitral valve pressure gradient at peak exercise.

Eligibility criteria:
inclusion criteria: 1. patients with mitral regurgitation and mitral valve prolapse who are scheduled for elective mitral valve repair by an experienced mitral valve repair surgeon (\>15 degenerative mitral valve repairs per year, with a repair rate\>90%, and able to perform mitral repair with either a leaflet resection or leaflet preservation strategy). 2. planned mitral valve repair amenable to either a leaflet resection or leaflet preservation surgical repair strategy exclusion criteria: 1. patients with anterior leaflet or commissural prolapse 2. patients with endocarditis or rheumatic mitral valve disease 3. patients with mitral annular calcification extending beyond the circumference of one leaflet scallop 4. patients with significant lv dysfunction defined as a lvef \<40% 5. patients undergoing concomitant aortic valve surgery 6. patients unable to undergo bicycle ergometry
combination treatment for advanced liver cancer

Conditions: Hepatocellular Carcinoma; Hepatic Portal Vein Tumor Invasion

Summary: the purpose of this study is to determine whether tace combined endovascular stent implantation confers a survival benefit over tace alone.


Eligibility criteria:
inclusion criteria: * (1) hepatocellular carcinoma(hcc) diagnosis confirmed by needle biopsy or by two coincidental imaging techniques associated with increased α-fetoprotein according to the american association for the study of liver diseases (aasld) guidelines and contrast-enhancing tumour thrombus within the main portal vein and one of the first-order branch on ct or mri; * (2) child-pugh classification grade a or b； * （3）eastern cooperative oncology group (ecog) performance status score of 2 or less. exclusion criteria: * advanced liver disease (bilirubin levels \>3 mg/dl, astor alt \>5 × upper limit of normal)； * tumor invade the inferior vena cava, extrahepatic spread; * contraindications for doxorubicin or oxaliplatin chemotherapy; * any contraindication to an arterial procedure such as impaired clotting tests (platelet count below 50 × 109/l or prothrombin activity below 50 %); * renal failure,cardiac ejection fraction \<50 %) or end-stage disease； * patients who were not capable of cooperation during the procedure.

Keywords: hepatocellular carcinoma portal vein tumor thrombosis stents chemoembolization